A recent Rheumatology digest,
as sent to subscribers

Study Type: Prospective observational cohort with single-cell RNA sequencing and plasma proteomic profiling (small sample; exploratory/mechanistic).

Key Question: What peripheral immune signatures distinguish ACPA+ at-risk individuals who imminently progress to RA, and do these differ by presence or absence of ultrasound-detectable subclinical synovitis?

Key Findings:

• US-negative imminent progressors (n=11) showed type I interferon upregulation in CD14+ classical monocytes and GZMK+ CD8+ T cells.
• US-positive progressors (n=11) showed a shift to IL-1β+ classical monocytes and clonal expansion of GZMB+ CD8+ T cells; GZMB+ and GZMK+ subsets were largely clonotypically distinct.
• Plasma proteomics showed a shift from Toll-like receptor-associated innate pathways (USneg) to effector and tissue-remodelling signatures (USpos).

Clinical Relevance: Identifies candidate biomarkers and pathway targets (e.g. IFN-I signalling) for risk stratification and prevention strategies in ACPA+ at-risk individuals, relevant to UK clinics managing arthralgia.

Limitations: Very small subgroups (n=11 each) and a single-timepoint comparison limit generalisability and causal inference; no validation cohort is reported.

Study Type: Narrative review of ongoing phase 2/3 drug trials and selected phase 1/2 cellular-therapy trials in systemic sclerosis (SSc).

Key Question: Which emerging therapies are in clinical development for SSc, and which disease mechanisms do they target?

Key Findings:

• Current approved options are organ-specific (e.g., tocilizumab and nintedanib for SSc-ILD); no therapy is approved for the disease as a whole.
• Newer agents are being developed against defined molecular and cellular pathways identified through advances in SSc pathogenesis.
• Patient stratification and personalised treatment are increasingly emphasised in trial design; cellular therapies, including CAR T-cell therapy, are highlighted as a significant innovation. The abstract gives no efficacy data, effect sizes or trial-level details.

Clinical Relevance: Gives UK rheumatologists a horizon-scan of the SSc pipeline, which may inform future trial referral and patient counselling, given limited disease-modifying options in routine NHS practice.

Limitations: Narrative review of ongoing trials without reported outcome data, so no conclusions on efficacy or safety can be drawn; the abstract does not describe the search method.

Study Type: Methodological viewpoint (expert opinion informed by narrative reviews); not original empirical research.

Key Question: How can acquisition, measurement and analytical "noise" be reduced to improve signal-to-noise ratio and credibility in rheumatology imaging studies?

Key Findings:

• Imaging research has prioritised sensitivity of techniques and scoring methods over constraining noise, despite regulatory emphasis on noise reduction for drug approval.
• The authors propose 10 expert-based rules covering image scoring, database handling and data analysis. Strategies include repeated scoring of existing images and correcting prior scoring or analytical errors.
• Credibility should rest on optimal signal-to-noise ratio, not on statistical model complexity or P values. Reader and analyst variability undermines the perceived objectivity of imaging endpoints.

Clinical Relevance: Clinicians appraising imaging endpoints in trials (e.g. radiographic progression, MRI scoring in axial SpA/RA) or designing local audits and research may find these rules a useful critical-appraisal framework.

Limitations: The rules are explicitly unvalidated methodological hypotheses requiring empirical testing; the abstract does not list them, so specifics cannot be assessed here.

Study Type: Translational laboratory study (scRNA-seq of synovial tissue and fluid, immunofluorescence, flow cytometry, and in vitro T-cell/macrophage coculture experiments).

Key Question: Which cells produce TNF in axSpA synovium, and what drives their phenotype?

Key Findings:

• CCL20+ macrophages were the predominant TNF-producing population in axSpA synovium (5 patients), with TNF protein confirmed in tissue and synovial fluid.
• Activated CD4+ T cells induced the CCL20+ phenotype via CD40L–CD40 signalling and an IL-1β/TNF-α autocrine loop, in both healthy control and axSpA-derived monocyte-derived macrophages.
• Circulating axSpA monocytes showed a higher baseline CCL20+ signature and greater TNF, IL-6, IL-1β and IL-23 production than healthy controls; these differences largely disappeared after T-cell induction or IL-1/TNF priming.

Clinical Relevance: This offers a mechanistic link between Th17 and TNF biology in axSpA and proposes circulating CCL20+ monocytes as a candidate biomarker of IL-1β/TNF-driven inflammation, which could eventually help stratify response to TNF or IL-17 inhibitors.

Limitations: Very small synovial sample (n=5) and in vitro mechanistic data, with no clinical outcome or treatment-response correlation, limit generalisability.

Study Type: Narrative review / perspective article (no original data).

Key Question: How can the Human Cell Atlas be adapted for musculoskeletal disease so that tissue-level cellular maps inform diagnosis, stratification and therapy?

Key Findings:

• Single-cell, spatial and multiomic studies are mapping MSK tissues (including bone marrow, muscle, osteoarthritis, rheumatoid arthritis, tendon disease and inflammatory fibrosis), suggesting that a single diagnostic label can hide distinct cellular mechanisms, while different diseases may share convergent stromal, immune, vascular or neuronal programmes.
• The authors propose a translational roadmap: define healthy reference tissue, identify disease-enriched cell states, nominate biomarkers and targets, then feed clinical trial outcomes back into the atlas.
• No quantitative outcomes are reported; the abstract presents a conceptual framework.

Clinical Relevance: It signals a possible shift towards classifying disease by pathogenic cell state, which could eventually inform mechanism-led stratification and trial design in UK rheumatology practice.

Limitations: As a conceptual review, it provides no prospective validation that atlas-derived cell states improve patient outcomes or can be implemented in routine care.

Study Type: Spatial transcriptomics discovery study (12 SRC with TMA, 6 lupus nephritis, 3 normal kidneys), with validation by multiplexed imaging in an expanded cohort.

Key Question: What are the spatially resolved cellular and molecular features of scleroderma renal crisis, and how do they differ from lupus nephritis?

Key Findings:

• SRC kidneys showed a triad of TMA, immune infiltration and fibrotic remodelling; complement activation, type I interferon signalling and fibrosis were shared with LN.
• SRC was distinguished by a vascular-hypoxic axis and glomerular niches featuring prominent myeloid cell interactions with parenchymal cells.
• Pathway upregulation was detectable in histologically mild lesions, with selective enrichment in glomerular TMA and arterial injury, converging on chronic injury/remodelling programmes.

Clinical Relevance: Identifies candidate mechanistic targets beyond ACE inhibition in a rare condition with high ESKD and mortality, though nothing here is yet actionable at the bedside.

Limitations: Very small discovery cohort of biopsy samples (disease-selected, TMA-pattern SRC only), with no clinical outcome or therapeutic data reported in the abstract.

Study Type: International consensus recommendations (EULAR-standard methodology) informed by systematic literature review; 30-member multidisciplinary task force.

Key Question: What is the appropriate role of imaging (ultrasound, MRI, FDG-PET) in diagnosing and assessing polymyalgia rheumatica?

Key Findings:

• Three overarching principles and seven recommendations were produced. PMR remains a clinical diagnosis; imaging is not needed to confirm PMR when clinical probability is high or to exclude it when low.
• Imaging is most useful at intermediate pretest probability (atypical presentations, suspected alternative or overlapping conditions). No modality was accurate enough for first-line use, so choice should reflect presentation, differentials, access, and local expertise.
• Vascular imaging is advised if giant cell arteritis overlap is suspected, but not for systematic screening for subclinical vasculitis. Imaging for monitoring or outcome prediction is not recommended.

Clinical Relevance: Supports selective, expertise-dependent imaging in UK practice, helping prioritise limited ultrasound and PET access for diagnostically uncertain cases.

Limitations: The abstract does not report evidence quality, vote agreement levels, or modality-specific accuracy data, so strength of evidence cannot be judged here.

Study Type: Cross-sectional diagnostic accuracy and reliability study (single-centre, n=69).

Key Question: How accurately does MRI-based synthetic CT (sCT) detect spinal new bone formation compared with T1-weighted MRI and radiography, using low-dose CT as the reference standard?

Key Findings:

• Sensitivity for new bone formation (NBF) was highest for sCT (70%), versus radiography (50% cervical/lumbar; 21% whole-spine) and T1wMRI (28%); specificity was ≥93% across modalities.
• Mean NBF count per participant: ldCT 25.8, sCT 24.0, T1wMRI 9.3, radiography 6.9.
• Reliability and inter-modality agreement between sCT and ldCT were excellent/substantial.

Clinical Relevance: sCT could allow structural damage assessment from MRI alone, avoiding additional radiation in younger axSpA/PsA patients, though it is not yet routine NHS practice.

Limitations: ldCT as reference standard, small mixed cohort, and 70% sensitivity mean sCT still misses substantial NBF, and clinical or prognostic validity was not assessed.